Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new method of treating wounds after major trauma costing nearly £150 per dressing is no more effective in reducing surgical infection rates than a standard wound dressing priced under £2, potentially saving the NHS millions.

© Shutterstock

Major trauma is where a patient suffers injuries to several different parts of their body at the same time or very serious injuries to just one part. Worldwide, it is the leading cause of death in people under 45 years and a significant cause of short and long-term disability. Major trauma is commonly associated with serious limb injuries such as fractured bones, but treatment of these fractures is complicated because the soft-tissues around the bone are also badly damaged. Serious wound healing complications such as deep infection are therefore common.

The type of dressing applied over the wound at the end of the operation may reduce the risk of infection. Negative pressure wound therapy (NPWT), which involves applying gentle suction to the surface of the wound as it heals, is a relatively new treatment that has provided promising early results in patients with surgical wounds associated with major trauma.

However, a new study from NDORMS finds that the use of incisional negative pressure wound therapy, compared with standard wound dressing, resulted in no significant difference in the rate of deep surgical site infection (SSI).

Each year the NHS spends between £4.5 - £5.1bn* on wound management. Because of the extra cost of suction pumps NPWT costs an average of £149.52, compared to £1.87 for standard dressings**. Exact figures on the number of NPWT dressings currently being used in the NHS is difficult to estimate, according to researchers, but millions of standard dressings are used in the NHS each year, with NPWT also being increasingly used. The researchers are due to publish a further economic analysis of the treatments later this year.

Lead author Professor Matthew Costa said: "Negative pressure wound therapy offered the prospect of reducing patients' risk of wound infection. However, we needed to be sure about this because the new dressings are more expensive than the current standard care. In the largest study of its kind we found no evidence that negative pressure dressings reduced the risk of deep infection in the surgical wound. The negative pressure dressings were very unlikely to be cost effective. This is important because the NHS spends millions of pounds on wound dressings each year. Using less costly standard treatment will mean savings for the NHS without compromising patient outcomes."

Professor Jason Madan from Warwick Medical School was the lead health economist for the WHIST trial. He said: "If the NHS stays with standard treatment, patients will be just as healthy, and the money that would have been spent on negative pressure wound therapy can be used in other ways that do improve patients' health."

The randomised clinical trial included 1548 participants each given either NPWT, or standard wound dressing, and the primary outcome measure was deep surgical site infection at 30 days. The research found no significant difference in the infection rate in the NPWT group at 5.84% and in the standard dressing group at 6.68%.

Professor Hywel Williams, Director of the NIHR Health Technology Assessment (HTA) Programme, which funded the research, said: "When most people think of research they usually think of developing new cures and tech innovations, but this valuable study shows that research into existing innovations that are being increasingly used in the NHS can be just as important."

The results of the trial have been published in the Journal of the American Medical Association (JAMA).

The trial was supported by the NIHR Oxford Biomedical Research Centre and the NIHR Clinical Research Network.

Results of the study are also being considered by the National Wound Care Strategy Programme as part of their evidence-based recommendations in developing guidelines for the use of NPWT for the NHS.

* The annual cost to the NHS of managing patients with wounds is between £4.5 billion -£5.1 billion. Guest, J. F., Ayoub, N., Mcllwraith, T., Uchegbu, I., Gerrish, A., Weidlich, D., Vowden, K. & Vowden, P. 2015. Health economic burden that wounds impose on the National Health Service in the UK. Downloaded from http://bmjopen.bmj.com/ on January 4, 2016 - Published by group.bmj.com

** NHS Supply Chain Catalogue Jan 2019 (average)

Similar stories

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.

NDORMS academics named NIHR Senior Investigators

Main

Congratulations to Professor Jonathan Rees who has been announced as a National Institute of Health Research (NIHR Senior Investigator).

New centre aims to help companies conduct more efficient trials

Botnar Main Trials

A new clinical therapeutics centre has been set up by the University of Oxford to help life sciences companies identify interventions that have the greatest potential to deliver patient benefit, and so bring down the cost of early phase clinical trials.

Cognitive–behavioural therapy consistently improves quality of life

Main Rehabilitation and self-management Research

A meta-review of the available research into cognitive behavioural therapy reveals it consistently improves health-related quality of life across different medical conditions and demographic populations.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

Main Research

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Versus Arthritis Foundation Fellowship awarded to Dr Kristina Zec

Awards Main

Dr Kristina Zec has been awarded a Versus Arthritis Foundation Fellowship to investigate the role of products of lipid oxidation produced by synovial macrophages in triggering articular inflammation.